Showing 473 results
-
Press release /New data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before…
-
Press release /EMA CHMP positive opinion paves way for Cosentyx® to become a first-line systemic treatment in pediatric psoriasis CHMP opinion based on two Phase III studies showing Cosentyx provides fast and…
-
Press release /Latest data show Cosentyx® provides fast and strong skin clearance, significant improvement in quality of life and a favorable safety profile1,2 Moderate-to-severe psoriasis affects more than…
-
Press release /New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide®* to Ultibro® Breezhaler® improved lung function and was well tolerated. The FLASH…
-
Press release /
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
Nearly 90% of first-line Kesimpta patients had no disability progression independent of relapse activity (PIRA) for up to six years in an analysis of open-label ALITHIOS extension study1More than 80… -
Press release /Basel, December 15, 2017 - Novartis announced today that Bruno Strigini, CEO Novartis Oncology has decided to retire from Novartis and the industry for personal reasons. Joseph Jimenez, CEO of…
-
Press release /Basel, 15. Dezember 2017 - Novartis gibt bekannt, dass sich Bruno Strigini, CEO Novartis Onkologie, entschieden hat, die Firma aus persönlichen Gründen zu verlassen und sich aus der Industrie…
-
Press release /Net sales grew 4% (cc[1], +10% USD) mainly driven by: Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide Cosentyx was USD 580 million, +35% (cc) with strong…
-
Press release /In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NET Approval helps fulfill unmet need as…
-
Press release /In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage[1] Advanced SM is rare and has a poor prognosis[…